Major efforts are currently ongoing to combine KRAS inhibitors with other molecularly targeted drugs of the Ras-MAPK pathway, chemotherapy, and immune checkpoint inhibitors.476 It is therefore expected that KRAS inhibitors will reshape the therapeutic landscape of KRAS mutant cancers of the gastrointestinal tract in the upcoming years. The gene discussed is KRAS; the disease is cancer.